Veterinary Medicines

BioBos Respi 3, Suspension for injection

Authorised
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
Download as PDF

Product identification

Medicine name:
BioBos Respi 3, Suspension for injection
BioBos Respi 3, süstesuspensioon veistele
Active substance:
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
Target species:
  • Cattle
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cattle
      • Milk
        0
        hour
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AL04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Plastic Vial 10 x 5.0 Dose
  • Plastic Vial 1 x 50.0 Dose
  • Plastic Vial 1 x 25.0 Dose
  • Plastic Vial 1 x 5.0 Dose
  • Plastic Vial 10 x 5.0 Dose
  • Glass Vial 10 x 5.0 Dose
  • Glass Vial 1 x 50.0 Dose
  • Glass Vial 1 x 25.0 Dose
  • Glass Vial 1 x 5.0 Dose
  • Glass Vial 10 x 5.0 Dose

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 2103
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0143/001
Concerned member states:
  • Estonia
  • Latvia
  • Lithuania

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 9/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."